Q-10 in de vorm van Ubiquinone dwingt prostaatkankercellen en borstkankercellen tot apoptose - zeflmoord van de kankercellen zonder de gezonde cellen aan te tasten.

21 april 2012: onderaan is een lijst toegevoegd van studies gedaan met Q-10

9 mei 2006: Bron: ASCO 2006

UM Researchers Present Dramatic Cancer Findings
Researchers from the University of Miami Leonard M. Miller School of Medicine have presented dramatic findings at a national cancer meeting that show a link between a very potent antioxidant that occurs naturally in the body, and the ability to kill breast and prostate cancer cells. The antioxidant they have studied is Ubiquinone, more commonly referred to as Coenzyme Q10 or CoQ10, and delivery of the therapy could soon be as simple as applying an ointment to the tumor site.

CoQ10 is one of the most important antioxidants found in the body, and is used by cells not only to protect against free radical damage, but also to produce ATP, a compound that powers every cell in the human body. High levels of CoQ10 are especially essential in the high activity cells, such as heart muscle cells, brain cells, and immune system cells. As we age, CoQ10 levels drop off, and decreased levels of the antioxidant have been observed in cancer, diabetes, and neurodegenerative diseases.

In laboratory and animal studies, the UM researchers found that by delivering CoQ10 to cancer cells and tissues, the molecule induced apoptosis, which is the normal programmed cell death that goes awry in the disease process. 'The most amazing part is that w've been able to restore a cancer cell's ability to kill itself, while not impacting normal cells' said Niven Narain, research associate in the Department of Dermatology and Cutaneous Surgery at the Miller School of Medicine.

The scientists made two presentations at the annual meeting of the American Association for Cancer Research in Anaheim, Ca. The first presentation involved the most common prostate cancer cell line, PC3. The researchers showed that adding CoQ10 to the cells.

References

Kessenbrock K, Plaks V, Werb Z. Bicknell R: Matrix Metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141:52–67. doi: 10.1016/j.cell.2010.03.015. [PMC free article] [PubMed] [Cross Ref]
Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 2009;27:5287–97. doi: 10.1200/JCO.2009.23.5556. [PMC free article] [PubMed] [Cross Ref]
Qian Q, Wang Q, Zhan P, Peng L, Wei SZ, Shi Y. The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis. Cancer Invest. 2010;28:661–9. doi: 10.3109/07357901003735634. [PubMed] [Cross Ref]
Ala-aho R, Kähäri VM. Collagenases in cancer. Biochimie. 2005;87:273–86. doi: 10.1016/j.biochi.2004.12.009. [PubMed] [Cross Ref]
Brown NS, Bicknell R. Hypoxia and oxidative stress in breast cancer Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001;3:323–7. doi: 10.1186/bcr315. [PMC free article] [PubMed] [Cross Ref]
Wu WS. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006;25:695–705. doi: 10.1007/s10555-006-9037-8. [PubMed] [Cross Ref]
Shekelle P, Hardy ML, Coulter I, Udani J, Spar M, Oda K. Effect of the supplemental use of antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cancer. Evid Rep Technol Assess (Summ) 2003;75:1–3. [PubMed]
Yuvaraj S, Premkumar VG, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins. Clin Biochem. 2007;40:623–8. doi: 10.1016/j.clinbiochem.2007.02.003. [PubMed] [Cross Ref]
Adhikary A, Mohanty S, Lahiry L, Hossain DM, Chakraborty S, Das T. Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk. FEBS Lett. 2010;584:7–14. doi: 10.1016/j.febslet.2009.10.081. [PubMed] [Cross Ref]
Chao HP, Kuo CD, Chiu JH, Fu SL. Andrographolide Exhibits Anti-Invasive Activity against Colon Cancer Cells via Inhibition of MMP2 Activity. Planta Med. 2010. in press . [PubMed]
Bentinger M, Brismar K, Dallner G. The antioxidant role of coenzyme Q. Mitochondrion. 2007. pp. S41–50. Epub 2007 Mar 16. [PubMed] [Cross Ref]
Littarru GP, Tiano L. Clinical aspects of coenzyme Q10: an update. Nutrition. 2010;26:250–4. doi: 10.1016/j.nut.2009.08.008. [PubMed] [Cross Ref]
Portakal O, Ozkaya O, Erden Inal M, Bozan B, Kosan M, Sayek I. coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem. 2000;33:279–284. doi: 10.1016/S0009-9120(00)00067-9. [PubMed] [Cross Ref]
Hertz N, Lister RE. Improved survival in patients with end-stage cancer treated with coenzyme Q(10) and other antioxidants: a pilot study. J Int Med Res. 2010;38:293.
Sachdanandam P. Antiangiogenic and hypolipidemic activity of coenzyme Q10 supplementation to breast cancer patients undergoing Tamoxifen therapy. Biofactors. 2008;32:151–9. doi: 10.1002/biof.5520320118. [PubMed] [Cross Ref]
Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy. Biol Pharm Bull. 2007;30:367–70. doi: 10.1248/bpb.30.367. [PubMed] [Cross Ref]
Premkumar VG, Yuvaraj S, Sathish S, Shanthi P, Sachdanandam P. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. Vascul Pharmacol. 2008;48:191–201. doi: 10.1016/j.vph.2008.02.003. [PubMed] [Cross Ref]
Rusciani L, Proietti I, Rusciani A, Paradisi A, Sbordoni G, Alfano C. Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression. J Am Acad Dermatol. 2006;54:234–41. doi: 10.1016/j.jaad.2005.08.031. [PubMed] [Cross Ref]
Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol. 1999;12:669–74. [PubMed]
Cheng CJ, Lin YC, Tsai MT, Chen CS, Hsieh MC, Chen CL. SCUBE2 suppresses breast tumor cell proliferation and confers a favorable prognosis in invasive breast cancer. Cancer Res. 2009;69:3634–41. doi: 10.1158/0008-5472.CAN-08-3615. [PubMed] [Cross Ref]
Bogani P, Canavesi M, Hagen TM, Visioli F, Bellosta S. Thiol supplementation inhibits metalloproteinase activity independent of glutathione status. Biochem Biophys Res Commun. 2007;363:651–5. doi: 10.1016/j.bbrc.2007.09.018. [PubMed] [Cross Ref]
Griffith OW. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med. 1999;27:922–35. doi: 10.1016/S0891-5849(99)00176-8. [PubMed] [Cross Ref]
Pei P, Horan MP, Hille R, Hemann CF, Schwendeman SP, Mallery SR. Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention. Free Radic Biol Med. 2006;41:1315–24. doi: 10.1016/j.freeradbiomed.2006.07.014. [PMC free article] [PubMed] [Cross Ref]
Das S, Banerji A, Frei E, Chatterjee A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008;82:467–76. doi: 10.1016/j.lfs.2007.12.013. Epub 2007 Dec 27. [PubMed] [Cross Ref]
Rosenkranz AR, Schmaldienst S, Stuhlmeier KM, Chen W, Knapp W, Zlabinger GJ. A microplate assay for the detection of oxidative products using 2',7'-dichlorofluorescin-diacetate. J Immunol Methods. 1992;156:39–45. doi: 10.1016/0022-1759(92)90008-H. [PubMed] [Cross Ref]
Factor VM, Kiss A, Woitach JT, Wirth PJ, Thorgeirsson SS. Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem. 1998;273:15846–53. doi: 10.1074/jbc.273.25.15846. [PubMed] [Cross Ref]
Kupai K, Szucs G, Hajdu I, Csonka C, Csont T. Matrix metalloproteinase activity assays: Importance of zymography. J Pharmacol Toxicol Methods. 2010;61:205–9. doi: 10.1016/j.vascn.2010.02.011. [PubMed] [Cross Ref]
Khorramizadeh MR, Pezeshki M, Ghahary A, Zeraati H, Berahmeh A. Determination of gelatinase A using a modified indirect hemagglutination assay in human prostate cancer screening and assessment of its correlation with prostate-specific antigen parameters. Int J Urol. 2005;12:637–43. doi: 10.1111/j.1442-2042.2005.01094.x. [PubMed] [Cross Ref]
Das S, Banerji A, Frei E, Chatterjee A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci. 2008;82:467–76. doi: 10.1016/j.lfs.2007.12.013. [PubMed] [Cross Ref]
Ortega A, Ferrer P, Carretero J, Obrador E, Asensi M, Pellicer JA. Down-regulation of glutathione and Bcl-2 synthesis in mouse B16 melanoma cells avoids their survival during interaction with the vascular endothelium. J Biol Chem. 2003;278:39591–9. doi: 10.1074/jbc.M303753200. [PubMed] [Cross Ref]
Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med. 2004;37:768–84. doi: 10.1016/j.freeradbiomed.2004.06.008. [PubMed] [Cross Ref]
Sandhya T, Mishra KP. Cytotoxic response of breast cancer cell lines, MCF 7 and T 47 D to triphala and its modification by antioxidants. Cancer Lett. 2006;238:304–13. doi: 10.1016/j.canlet.2005.07.013. [PubMed] [Cross Ref]
Voronkina IV, Kirpichnikova KM, Smagina LV, Gamaliĭ IA. Changes in matrix metalloproteinases activities in normal and transformed mouse fibroblasts under effect of antioxidants. Tsitologiia. 2008;50:877–81. [PubMed]
Bogani P, Canavesi M, Hagen TM, Visioli F, Bellosta S. Thiol supplementation inhibits metalloproteinase activity independent of glutathione status. Biochem Biophys Res Commun. 2007;363:651–5. doi: 10.1016/j.bbrc.2007.09.018. [PubMed] [Cross Ref]
Tyagi SC, Kumar S, Borders S. Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J Cell Biochem. 1996;61:139–51. doi: 10.1002/(SICI)1097-4644(19960401)61:1<139::AID-JCB15>3.0.CO;2-J. [PubMed] [Cross Ref]
Lazo JS, Kuo SM, Woo ES, Pitt BR. The protein thiol metallothionein as an antioxidant and protectant against antineoplastic drugs. Chem Biol Interact. 1998;111-112:255–262. doi: 10.1016/S0009-2797(97)00165-8. [PubMed] [Cross Ref]
Brenneisen P, Briviba K, Wlaschek M, Wenk J, Scharffetter-Kochanek K. Hydrogen peroxide (H2O2) increases the steady-state mRNA levels of collagenase/MMP-1 in human dermal fibroblasts. Free Radic Biol Med. 1997;22:515–24. doi: 10.1016/S0891-5849(96)00404-2. [PubMed] [Cross Ref]
Wenk J, Brenneisen P, Wlaschek M, Poswig A, Briviba K, Oberley TD. Stable overexpression of manganese superoxide dismutase in mitochondria identifies hydrogen peroxide as a major oxidant in the AP-1-mediated induction of matrix-degrading metalloprotease-1. J Biol Chem. 1999;274:25869–76. doi: 10.1074/jbc.274.36.25869. [PubMed] [Cross Ref]
Schmelzer C, Lindner I, Rimbach G, Niklowitz P, Menke T, Döring F. Functions of coenzyme Q10 in inflammation and gene expression. Biofactors. 2008;32:179–83. doi: 10.1002/biof.5520320121. [PubMed] [Cross Ref]
Factor VM, Kiss A, Woitach JT, Wirth PJ, Thorgeirsson SS. Disruption of redox homeostasis in the transforming growth factor-alpha/c-myc transgenic mouse model of accelerated hepatocarcinogenesis. J Biol Chem. 1998;273:15846–53. doi: 10.1074/jbc.273.25.15846. [PubMed] [Cross Ref]
Linnane AW, Kios M, Vitetta L. Coenzyme Q10 - its role as a prooxidant in the formation of superoxide anion/hydrogen peroxide and the regulation of the metabolome. Mitochondrion. 2007. pp. S51–61. Epub 2007 Mar 30. [PubMed] [Cross Ref]
Abbasi N, Khaghani S, Sharif-Tabrizi A, Farzami B, Vardasbi S, Bahar M. et al. Comparison of Lipoamide dehydrogenase activity in HL-60 Leukemia cells and normal lymphocyte. Acta Medica Iranica. 2007;45:282–284.